Back to Journals » Pharmacogenomics and Personalized Medicine » Volume 10

Updating the landscape of direct-to-consumer pharmacogenomic testing

Authors Filipski KK, Murphy JD, Helzlsouer KJ

Received 26 April 2017

Accepted for publication 10 July 2017

Published 22 August 2017 Volume 2017:10 Pages 229—232

DOI https://doi.org/10.2147/PGPM.S140461

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Lucy Goodman

Peer reviewer comments 2

Editor who approved publication: Dr Martin Bluth


Kelly K Filipski, John D Murphy, Kathy J Helzlsouer

Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA

Abstract: Pharmacogenomics has identified important drug–gene interactions that affect the safety and efficacy of medications. Direct-to-consumer genetic testing, when first introduced, included some pharmacogenomic-related genes. The current landscape of pharmacogenomic direct-to-consumer testing is reviewed. Prior published reviews of the literature were updated through February 2017 and a scan of the current availability of direct-to-consumer genomic testing by companies was conducted. Results of the review demonstrate a shift toward physician-approved ordering.

Keywords: pharmacogenomics, direct-to-consumer testing
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]